Ad is loading...
AKBA
Price
$1.82
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
110 days until earnings call
INZY
Price
$2.69
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
118 days until earnings call
Ad is loading...

AKBA vs INZY

Header iconAKBA vs INZY Comparison
Open Charts AKBA vs INZYBanner chart's image
Akebia Therapeutics
Price$1.82
Change-$0.00 (-0.00%)
Volume$1.44M
CapitalizationN/A
Inozyme Pharma
Price$2.69
Change-$0.00 (-0.00%)
Volume$371.49K
CapitalizationN/A
AKBA vs INZY Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AKBA vs. INZY commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and INZY is a Buy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (AKBA: $1.82 vs. INZY: $2.69)
Brand notoriety: AKBA and INZY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 77% vs. INZY: 138%
Market capitalization -- AKBA: $397.09M vs. INZY: $179.23M
AKBA [@Biotechnology] is valued at $397.09M. INZY’s [@Biotechnology] market capitalization is $179.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileINZY’s FA Score has 1 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • INZY’s FA Score: 1 green, 4 red.
According to our system of comparison, both AKBA and INZY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 5 TA indicator(s) are bullish while INZY’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 5 bullish, 6 bearish.
  • INZY’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, AKBA is a better buy in the short-term than INZY.

Price Growth

AKBA (@Biotechnology) experienced а -2.15% price change this week, while INZY (@Biotechnology) price change was -21.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

AKBA is expected to report earnings on Mar 12, 2025.

INZY is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($410M) has a higher market cap than INZY($181M). AKBA YTD gains are higher at: 46.774 vs. INZY (-36.854). AKBA has higher annual earnings (EBITDA): 4.3M vs. INZY (-90.3M). INZY has more cash in the bank: 132M vs. AKBA (34M). INZY (46.8M) and AKBA (48.6M) have identical debt. AKBA has higher revenues than INZY: AKBA (170M) vs INZY (0).
AKBAINZYAKBA / INZY
Capitalization410M181M227%
EBITDA4.3M-90.3M-5%
Gain YTD46.774-36.854-127%
P/E RatioN/AN/A-
Revenue170M0-
Total Cash34M132M26%
Total Debt48.6M46.8M104%
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBAINZY
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 19 days ago
86%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEQIX16.750.21
+1.27%
Glenmede Equity Income
MECVX15.480.14
+0.91%
NYLI Epoch Capital Growth Investor Class
PSLGX154.221.18
+0.77%
Putnam Sustainable Leaders R6
GRMIX28.520.16
+0.56%
Nationwide S&P 500 Index R6
INFFX9.60N/A
N/A
Tortoise Energy Infrastructure and Inc C

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+1.68%
ABOS - AKBA
43%
Loosely correlated
-2.53%
BEAM - AKBA
41%
Loosely correlated
-3.72%
ABCL - AKBA
40%
Loosely correlated
+1.87%
INZY - AKBA
40%
Loosely correlated
-3.58%
KOD - AKBA
36%
Loosely correlated
+1.90%
More

INZY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with BEAM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
-3.58%
BEAM - INZY
56%
Loosely correlated
-3.72%
FATE - INZY
49%
Loosely correlated
-6.76%
ABOS - INZY
49%
Loosely correlated
-2.53%
DNLI - INZY
49%
Loosely correlated
-0.82%
PGEN - INZY
48%
Loosely correlated
+7.91%
More